We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Functions of PPARγ
- Role of PPARγ in adipocytes and glucose homeostasis
- Role of PPARγ in macrophage functions
- PPARγ targeting drugs
- PPARγ in MAFLD
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Merk, D. (2026, October 29). Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 29, 2026, from https://doi.org/10.69645/LKCG8126.Export Citation (RIS)
Publication History
- Published on October 29, 2026
Financial Disclosures
- Daniel Merk discloses affiliations with Ludwig-Maximilians-University Munich and the Free State of Bavaria. He is a member of the German Pharmaceutical Society (DPhG) and the German Chemical Society (GDCh). He has received honoraria for lectures, authoring, reviewing, and advisory activities from the DPhG, German Associations of Pharmacists, German Medical Association, Sanofi, Boehringer Ingelheim, ONO Pharmaceuticals, YS Life Science, AVOXA, SpringerNature, Wiley, and the Swiss National Science Foundation (SNF). Additionally, he holds five patents or patent applications related to nuclear receptor modulators and other small molecule drugs. His research is funded by the European Research Council (ERC), Innovative Medicines Initiative (IMI), German Research Foundation (DFG), German Federal Agency for Disruptive Innovation (SPRIN-D), and Immunic AG.
Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs
Published on October 29, 2026
7 min